Jump to content

Alltrials update: Pharma company investors call for clinical trials transparency

Recommended Posts


About 30% of a drug company’s valuation is based on results from its Phase-III trials (when drugs are extensively tested in humans). Investors are now urging the industry to disclose more data, both to ensure more accurate valuations and to lower the risk of future litigation.

The evidence base for new medicines is flawed. Time to fix it


The motive is questionable but the outcome is the one we want.

Share this post

Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...

Important Information

Terms of Use Privacy Policy